American pharmaceutical major Merck & Co is acquiring clinical-stage biopharmaceutical firm Imago BioSciences, a portfolio company of Malaysian venture capital firm Xeraya Capital, for $1.35 billion in cash.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
